About AZRX

AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD recombinant lipase for EPI is the Company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AZRX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.0% 0 8 K 8384
IWC iShares Microcap ETF 914.4 M 9.14374E+08 1,451 1451 0.01% 0.0001 52 K 51532

Wait, Before You Leave...